Trial
NCT05013554
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sanofi
Collaborators
—
Condition
Neoplasm Malignant
Intervention
SAR443216 IV
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-15